Literature DB >> 20384533

Renal toxicity associated with tenofovir use.

Sonia Rodriguez-Nóvoa1, Elena Alvarez, Pablo Labarga, Vincent Soriano.   

Abstract

IMPORTANCE OF THE FIELD: Tenofovir (TFV) is a nucleotide analogue widely used for the treatment of HIV infection. Despite its proven efficacy and safety, cases of kidney tubular dysfunction have increasingly been reported and concern exists about the risk of nephrotoxicity associated with the long-term use of TFV. AREAS COVERED IN THIS REVIEW: Evidences about the renal toxicity associated with TFV use as well as predictors are examined. The most relevant publications assessing TFV safety and those which have reported cases of tubular dysfunction were identified and carefully revised. WHAT THE READER WILL GAIN: Renal damage of clinical significance caused by TFV is uncommon in the short-mid-term. It occurs more frequently in subjects with underlying kidney conditions. TFV primarily results in kidney tubular dysfunction and less frequently in glomerular abnormalities. Kidney damage may progress over time under long-term TFV exposure but is reversible in most cases on drug discontinuation. TAKE HOME MESSAGE: Severe renal damage associated with TFV use is uncommon and of multifactorial origin. However, mild tubular dysfunction is recognized in a substantial proportion of TFV-treated individuals and tends to increase with cumulative exposure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20384533     DOI: 10.1517/14740331003627458

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  45 in total

Review 1.  Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.

Authors:  Maxwell O Akanbi; Kimberly K Scarsi; Kimberly Scarci; Babafemi Taiwo; Robert L Murphy
Journal:  Expert Opin Pharmacother       Date:  2012-01       Impact factor: 3.889

Review 2.  Renal disease in HIV-infected individuals.

Authors:  John Phair; Frank Palella
Journal:  Curr Opin HIV AIDS       Date:  2011-07       Impact factor: 4.283

3.  HIV and mitochondria: more than just drug toxicity.

Authors:  Todd Hulgan; Mariana Gerschenson
Journal:  J Infect Dis       Date:  2012-04-03       Impact factor: 5.226

4.  Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.

Authors:  Pedro Rodríguez Quesada; Laura López Esteban; Jimena Ramón García; Rocío Vázquez Sánchez; Teresa Molina García; Gabriel Gaspar Alonso-Vega; Javier Sánchez-Rubio Ferrández
Journal:  Int J Clin Pharm       Date:  2015-05-26

Review 5.  Update on tenofovir toxicity in the kidney.

Authors:  Andrew M Hall
Journal:  Pediatr Nephrol       Date:  2012-08-10       Impact factor: 3.714

Review 6.  HIV therapies and the kidney: some good, some not so good?

Authors:  Lene Ryom; Amanda Mocroft; Jens Lundgren
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

Review 7.  Initiating antiretrovirals during tuberculosis treatment: a drug safety review.

Authors:  Tanuja N Gengiah; Andrew L Gray; Kogieleum Naidoo; Quarraisha Abdool Karim
Journal:  Expert Opin Drug Saf       Date:  2011-01-05       Impact factor: 4.250

8.  Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).

Authors:  F Touzard Romo; L M Smeaton; T B Campbell; C Riviere; R Mngqibisa; M Nyirenda; K Supparatpinyo; N Kumarasamy; J G Hakim; T P Flanigan
Journal:  HIV Clin Trials       Date:  2014 Nov-Dec

Review 9.  The other genome: a systematic review of studies of mitochondrial DNA haplogroups and outcomes of HIV infection and antiretroviral therapy.

Authors:  Anna B Hart; David C Samuels; Todd Hulgan
Journal:  AIDS Rev       Date:  2013 Oct-Dec       Impact factor: 2.500

10.  Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection.

Authors:  Murli Purswani; Kunjal Patel; Jeffrey B Kopp; George R Seage; Miriam C Chernoff; Rohan Hazra; George K Siberry; Lynne M Mofenson; Gwendolyn B Scott; Russell B Van Dyke
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.